Alvotech will be recruiting 50 new employees for its new state-of-the-art biomanufacturing facility in the science park of the University of Iceland in Reykjavik over the coming months. Some 35 of these positions have already been advertised, reaching out to university graduates with scientific backgrounds and the recruitment process will continue in the first half of next year.
A total of 200 new jobs are expected to be created in connection with the company’s operations over the coming years. Interested candidates can apply for these new Alvotech positions on the company’s website.
Construction of Alvotech’s vast 13,000 m2 high-tech facility commenced in November 2013. The complex will be used for the development and production of biosimilar molecules and operations in the facility are scheduled to begin in early 2016. Six key biosimilar molecules are currently being developed by Alvotech in collaboration with global partners and the company’s first product will go to market in 2019 when patents expire in key markets. Global brand sales for molecules in Alvotech‘s pipeline in 2013 amounted to EUR 15 billion.